13 research outputs found

    Показатели липидного состава кожного барьера у новорожденных детей

    Get PDF
    Study results of neutral lipids of superficial hydro-lipid film (SHLF) in healthy newborns ( n = 46), in the children with severe allergic history ( n = 29), in newborns with toxic erythema ( n = 34) and nappies dermatitis ( n = 29) are presented in the article. The study is performed using thin-layer chromatography. Marked changes in lipid structure of dermal SHLF in all children in comparison with controls are revealed which needs further observation and correction.Представлены результаты исследования нейтральных липидов поверхностной гидролипидной пленки (ПГЛП) кожи у здоровых новорожденных ( n = 46), у детей с отягощенным аллергоанамнезом ( n = 29), у новорожденных с токсической эритемой ( n = 34) и пеленочным дерматитом ( n = 29), выполненного методом тонкослойной хроматографии. Выявлены значительные изменения в липидном составе ПГЛП кожи у обследуемых детей всех групп в сравнении с контролем, что требует дальнейшего наблюдения и своевременной коррекции

    Networks of Emotion Concepts

    Get PDF
    The aim of this work was to study the similarity network and hierarchical clustering of Finnish emotion concepts. Native speakers of Finnish evaluated similarity between the 50 most frequently used Finnish words describing emotional experiences. We hypothesized that methods developed within network theory, such as identifying clusters and specific local network structures, can reveal structures that would be difficult to discover using traditional methods such as multidimensional scaling (MDS) and ordinary cluster analysis. The concepts divided into three main clusters, which can be described as negative, positive, and surprise. Negative and positive clusters divided further into meaningful sub-clusters, corresponding to those found in previous studies. Importantly, this method allowed the same concept to be a member in more than one cluster. Our results suggest that studying particular network structures that do not fit into a low-dimensional description can shed additional light on why subjects evaluate certain concepts as similar. To encourage the use of network methods in analyzing similarity data, we provide the analysis software for free use (http://www.becs.tkk.fi/similaritynets/)

    Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level

    No full text
    Vaccination against COVID-19 has occurred in Russia for more than two years. According to the Russian official clinical guidelines to maintain tense immunity in the conditions of the ongoing COVID-19 pandemic, it is necessary to use booster immunization six months after primary vaccination or a previous COVID-19 contraction. It is especially important to ensure the maintenance of protective immunity in the elderly, who are at risk of severe courses of COVID-19. Meanwhile, the immunological effectiveness of the booster doses has not been sufficiently substantiated. To investigate the immunogenicity of Sputnik V within the recommended revaccination regimen and evaluate the effectiveness of booster doses, we conducted this study on 3983 samples obtained from individuals previously vaccinated with Sputnik V in Moscow. We analyzed the level of antibodies in BAU/mL three times: (i) six months after primary immunization immediately before the booster (RV), (ii) 3 weeks after the introduction of the first component of the booster (RV1), and (iii) 3 weeks after the introduction of the second component of the booster (RV2). Six months after the primary vaccination with Sputnik V, 95.5% of patients maintained a positive level of IgG antibodies to the receptor-binding domain (RBD) of SARS-CoV-2. The degree of increase in the specific virus-neutralizing antibodies level after revaccination increased with a decrease in their initial level just before the booster dose application. In the group of people with the level of antibodies up to 100 BAU/mL six months after the vaccination, a more than eightfold increase (p p p p < 0.05), regardless of the previous COVID-19 infection. Thus, revaccination is most effective in individuals with an antibody level below 500 BAU/mL, regardless of the vaccinee age and COVID-19 contraction. For the first time, it has been shown that a single booster dose of the Sputnik vaccine is sufficient to form a protective immunity in most vaccinees regardless of age and preexisting antibody level

    Dynamics of SARS-CoV-2 Major Genetic Lineages in Moscow in the Context of Vaccine Prophylaxis

    No full text
    Findings collected over two and a half years of the COVID-19 pandemic demonstrated that the level immunity resulting from vaccination and infection is insufficient to stop the circulation of new genetic variants. The short-term decline in morbidity was followed by a steady increase. The early identification of new genetic lineages that will require vaccine adaptation in the future is an important research target. In this study, we summarised data on the variability of genetic line composition throughout the COVID-19 pandemic in Moscow, Russia, and evaluated the virological and epidemiological features of dominant variants in the context of selected vaccine prophylaxes. The prevalence of the Omicron variant highlighted the low effectiveness of the existing immune layer in preventing infection, which points to the necessity of optimising the antigens used in vaccines in Moscow. Logistic growth curves showing the rate at which the new variant displaces the previously dominant variants may serve as early indicators for selecting candidates for updated vaccines, along with estimates of efficacy, reduced viral neutralising activity against the new strains, and viral load in previously vaccinated patients

    Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance

    No full text
    Mass vaccination campaigns against COVID-19 affected more than 90% of the population in most developed countries. The new epidemiologic wave of COVID-19 has been ongoing since the end of 2021. It is caused by a virus variant B.1.1.529, also known as &ldquo;Omicron&rdquo; and its descendants. The effectiveness of major vaccines against Omicron is not known. The purpose of this study is to evaluate the efficacy of the Sputnik V vaccine. The main goal is to assess its protection against hospitalization in the period of Omicron dominance. We conducted our study based on a large clinical center in Moscow (Russia) where 1112 patients were included. We used the case-population method to perform the calculations. The data we obtained indicate that the Omicron variant causes at least 90% of infections in the studied cohort. The effectiveness of protection against hospitalization with COVID-19 in our study was 85.9% (95% CI 83.0&ndash;88.0%) for those who received more than one dose. It was 87.6% (95% CI 85.4&ndash;89.5%) and 97.0% (95% CI 95.9&ndash;97.8%) for those who received more than two or three doses. The effectiveness in cases of more severe forms was higher than for less severe ones. Thus, present study indicates the high protective efficacy of vaccination against hospitalization with COVID-19 in case of Omicron lineage

    DataSheet_1_Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus.docx

    No full text
    WHO has declared the outbreak of monkeypox as a public health emergency of international concern. In less than three months, monkeypox was detected in more than 30 000 people and spread to more than 80 countries around the world. It is believed that the immunity formed to smallpox vaccine can protect from monkeypox infection with high efficiency. The widespread use of Vaccinia virus has not been carried out since the 1980s, which raises the question of the level of residual immunity among the population and the identification of groups requiring priority vaccination. We conducted a cross-sectional serological study of remaining immunity among Moscow residents. To do this, a collection of blood serum samples of age group over 30 years old was formed, an in-house ELISA test system was developed, and a virus neutralization protocol was set up. Serum samples were examined for the presence of IgG antibodies against Vaccinia virus (n=2908), as well as for the ability to neutralize plaque formation with a Vaccinia virus MNIIVP-10 strain (n=299). The results indicate the presence of neutralizing antibody titer of 1/20 or more in 33.3 to 53.2% of people older than 45 years. Among people 30-45 years old who probably have not been vaccinated, the proportion with virus neutralizing antibodies ranged from 3.2 to 6.7%. Despite the higher level of antibodies in age group older than 66 years, the proportion of positive samples in this group was slightly lower than in people aged 46-65 years. The results indicate the priority of vaccination in groups younger than 45, and possibly older than 66 years to ensure the protection of the population in case of spread of monkeypox among Moscow residents. The herd immunity level needed to stop the circulation of the virus should be at least 50.25 – 65.28%.</p
    corecore